GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8

October 28, 2015 11:02 AM

Canaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found